Bradley Merrill Thompson, a Member of the Firm in the Health Care and Life Sciences practice, in the firm’s Washington, DC, office, was quoted in FDA News, in “One In, Two Out Executive Order Will Likely Increase Use of Internal FDA Communications.” (Read the full version – subscription required.)
Following is an excerpt:
President Donald Trump’s executive order on new regulations will likely lead to increased use of internal communications to make drug policy at the FDA, an expert said at an FDAnews conference on drug-device combination products last week.